# MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

> **NCT02391038** · PHASE1 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Advanced Gastrointestinal Carcinoma
- Gastroesophageal Junction Adenocarcinoma
- Recurrent Gastric Adenocarcinoma
- Recurrent Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Recurrent Gastrointestinal Carcinoma

## Interventions

- **DRUG:** MLN0264

## Key facts

- **NCT ID:** NCT02391038
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study was terminated because preliminary PK and overall clinical data demonstrated compelling similarity between Western and Asian participant populations.
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02391038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02391038, "MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02391038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*